Nkarta to Host Conference Call Highlighting Preliminary Clinical Data from Two Lead NK Cell Therapy Candidates
SOUTH SAN FRANCISCO, Calif., April 22, 2022 – Nkarta, Inc. (Nasdaq: NKTX) will hold a conference call on April 25, 2022, at 8:00 a.m. ET to discuss clinical data from ongoing Phase 1 trials for its lead programs, NKX101 and NKX019. Leading investigators will join management for the update. NKX101 targets NKG2D ligands in patients with acute myeloid leukemia and myelodysplastic syndromes, while NKX019 targets CD19 in B cell malignancies. The results will provide insights into the safety and anti-tumor activity of these investigational therapies.
- Conducting a conference call to discuss Phase 1 clinical trial data indicates transparency and engagement with investors.
- NKX101 and NKX019 are progressing in clinical trials, potentially leading to breakthroughs in treating specific cancers.
- None.
Call scheduled for Monday, April 25, 2022 8:00 a.m. ET
Clinical trial investigators to participate
SOUTH SAN FRANCISCO, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will host a conference call on Monday, April 25, 2022 at 8:00 a.m. ET to review clinical data from its ongoing Phase 1 clinical trials assessing two lead clinical programs, NKX101 and NKX019. Leading investigators from the two clinical trials will join management for the discussion.
Conference Call and Webcast
To access the conference call, please dial:
+1 (866) 518-6930 (domestic)
+1 (203) 518-9797 (international)
Conference ID “Nkarta”
A simultaneous webcast of the conference call and accompanying slides will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately four weeks.
About NKX101
NKX101, a wholly owned program of Nkarta, is a healthy donor-derived CAR-NK investigational therapy targeting NKG2D ligands on tumor cells. NKX101 is being investigated in an ongoing Phase 1 single-arm, multi-center, open label clinical trial that is designed to assess the safety and anti-tumor activity of NKX101 as a multi-dose, multi-cycle monotherapy in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic syndromes (MDS).
About NKX019
NKX019, a wholly owned program of Nkarta, is a healthy donor-derived CAR-NK investigational therapy targeting CD19. NKX019 is being investigated in an ongoing Phase 1 single-arm, multi-center, open label clinical trial that is designed to assess the safety and anti-tumor activity of NKX019 as a multi-dose, multi-cycle monotherapy in patients with relapsed/refractory B cell malignancies.
About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.
Nkarta Media/Investor Contact:
Greg Mann
Nkarta, Inc.
gmann@nkartatx.com
FAQ
What is the purpose of Nkarta's clinical trials for NKX101 and NKX019?
When will Nkarta discuss its clinical trial results?
What are the targets of NKX101 and NKX019?
How can investors access the Nkarta conference call?
What type of company is Nkarta?
